SNTI — Senti Biosciences Holdings Share News
0.000.00%
Last trade - 00:00- $33.95m
- $25.01m
- $0.02m
U.S. STOCKS ON THE MOVE-Lululemon Athletica, cruise stocks, Super Micro
U.S. STOCKS ON THE MOVE-Intel, PTC Therapeutics, Senti Bio
Senti Bio soars after cancer therapy shows promise in early-stage trial
Brief: Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML
Brief: Senti Biosciences Regains Compliance With Nasdaq Listing Rule
Brief: Senti Bio Announces Reverse Stock Split
Brief: Senti Biosciences Appoints Kanya Rajangam As President Of Company
Brief: Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Brief: Senti Biosciences Q1 Net Income USD -12.111 Million
Brief: Senti Biosciences Says CFO Deborah Knobelman Notified Co Of Decision To Resign From Company
Brief: Senti Biosciences Q4 Net Income USD -18.716 Million
Brief: Senti Bio Announces Strategic Steps To Prioritize Investment In Lead Clinical Program
U.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
Senti Bio rises on FDA clearance to start trials on blood cancer therapy
U.S. STOCKS ON THE MOVE-Rocket Lab, Occidental, Nike
Brief: Senti Bio Announces FDA Clearance of IND Application for SENTI-202
Brief: Senti Bio Announces New Strategic Collaboration With Celest Therapeutics For Clinical Development Of Senti-301A In China
Brief: Senti Bio Announces Multiple Data Presentations At The Society For Immunotherapy Of Cancer Annual Meeting
Senti Biosciences Inc reports results for the quarter ended in June - Earnings Summary